Kinase Inhibitors

PrEST Antigen CDKN1B cyclin-dependent kinase inhibitor 1B (p

PrEST Antigen CDKN1C cyclin-dependent kinase inhibitor 1C (p

PrEST Antigen CDKN2D cyclin-dependent kinase inhibitor 2D (p

A cell-permeable triarylimidazole compound that acts as a reversible, ATP-competitive, and highly potent inhibitor of Raf kinase (IC 50 = 10 nM &amp K d = 2.4 nM for B-raf) with 7-, 30-, and 70-fold selectivity over p38&#945, GSK-3&#946, and

A potent, cell-permeable, reversible, and ATP-competitive cRAF1 kinase inhibitor (IC 50 = 9 nM). Shows &#8805100-fold selectivity for Raf kinase versus Cdk1, Cdk2, c-Src, ERK2, MEK, p38, Tie2, VEGFR2, and c-Fms.

A cell-permeable compound that specifically, reversibly, and stoichiometrically (1:1) binds to the GDP-bound Ral A/B in an allosteric manner (K d = 7.7 &#181M) and blocks its activation.

A cell-permeable isoquinolinesulfonamide compound that acts as a highly specific, reversible, potent, and ATP-competitive inhibitor of G-protein Rho-associated kinase (ROCK K i = 1.6 nM).

A cell-permeable isoquinolinesulfonamide compound that acts as a highly specific, reversible, potent, and ATP-competitive inhibitor of G-protein Rho-associated kinase (ROCK K i = 1.6 nM).

A cell-permeable indolopyridine compound that acts as a selective, reversible, and ATP-competitive inhibitor of Rho kinase activity with an IC 50 of 25 &#181M. Does not inhibit the activation of Rho kinase nor does it affect the in vitro

A cell-permeable pyridylthiazolyl-urea that acts as a potent, ATP site-targeting, Rho Kinase inhibitor (IC 50 = 14.5 and 6.

The racemic mixture of a cell-permeable dihydropteridinone that acts as a potent and selective RSK inhibitor (IC 50 &#880431 nM against RSK1, 2, 3, and 4 [ATP] = 100 &#181M) by targeting RSK N-terminal kinase domain in an ATP-competitive manner,

A cell-permeable Kaempferol (Cat. No.